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Abstract
Purpose: To evaluate the efficacy of computed tomography (CT)- and magnetic resonance imaging (MRI)-guided 
interstitial high-dose-rate brachytherapy (HDR IBT = IBT) in patients with metastatic esophageal squamous cell car-
cinoma.
Material and methods: Eleven patients with 21 unresectable metastases of histologically proven esophageal squa-
mous cell carcinoma were included in this retrospective study. Fourteen visceral and 7 lung metastases were treated 
with image-guided (CT or open MRI guidance) IBT using a 192Iridium source (single fraction irradiation). Clinical and 
imaging follow-up were performed every 3 months after treatment. Primary endpoint was local tumor control (LTC) 
and safety. Furthermore, we analyzed safety, progression-free survival (PFS), and overall survival (OS).
Results: The median diameter of the target lesions was 2.2 cm (range: 0.7-6.8 cm), treated with a median D100 of 
20.1 Gy (range: 10-25 Gy). During a median follow-up of 6.3 months (range: 3-21.8 months), three patients displayed 
local recurrences, resulting in LTC of 85.7%. Median PFS was 3.4 months and median OS after IBT was 13.7 months. 
No severe adverse events (grade 3+) requiring hospitalization or invasive intervention were recorded.
Conclusions: Image-guided IBT is a safe and effective treatment in patients with metastasized esophageal squa-
mous cell carcinoma.
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Purpose
Esophageal cancer (EC) is the eighth most common 
cancer worldwide. With an overall 5-year survival rate 
of 15-25%, it is the sixth leading cause of cancer-associ-
ated mortality [1]. These epidemiological data include 
both histological subtypes: adenocarcinoma (AC) and 
squamous cell carcinoma (SCC), which is the predomi-
nant type [2]. Multimodal therapy combining (neoad-
juvant) chemo-/radiotherapy and resection improves 
the outcome in non-metastatic patients [3]. However, 
up to 88.9% of the patients develop metastases within 
3 years after curative surgery, with a median disease-free 
interval after surgery of 1 year [4,5,6,7]. Due to limited 
therapy options, the prognosis after recurrence is ex-
tremely poor, with a median survival of 3-7 months 
[8,9,10]. Moreover, guidelines from the European Soci-
ety for Medical Oncology (ESMO) report that palliative 
chemotherapy for stage IV patients is less effective for 
SCC than for AC. Cisplatin-based combinations tend to 
show an increased response rate but no benefit regarding 
survival; therefore, either best supportive care or mono-
therapy should be considered in ESCC [11]. In contrast, 
in various tumor entities metastases limited in number 
and extent (i.e. oligometastases) are increasingly consid-
ered suitable for localized therapy with possible curative 
intent or at least systemic control, e.g. colorectal cancer 
[12,13]. Such localized therapy might include surgery but 
also image-guided local ablation techniques like radiof-
requency ablation or high-dose-rate brachytherapy (IBT). 
However, resection is not possible in majority of patients 
due to distribution of metastases, contraindications for 
surgery, or general anesthesia, apart from surgery-asso-
ciated morbidity and mortality. IBT of parenchymal or-
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gans is a relatively new technique, where an 192Iridium 
source is inserted directly in metastatic lesion through 
percutaneously implanted applicators, placed in an im-
age-guided minimal invasive intervention, and allowing 
a well-defined single fraction irradiation of the target 
volume. IBT has already been shown to be an efficient, 
yet gentle treatment with a minimum of complications in 
ablation of metastases of various tumors, e.g. colorectal 
cancer or malignant melanoma, or even gastroesophage-
al adenocarcinoma [14,15,16]. To our knowledge, no data 
has been published so far evaluating the efficacy of IBT 
in the treatment of visceral and lung metastases of SCC. 
In this study, we analyzed safety and efficacy in a cohort 
of 11 patients with 21 unresectable SCC metastases, who 
underwent image-guided IBT.
Material and methods
Eligibility criteria and patients 
Inclusion criteria were: 1. Technically unrespectable 
metastases; 2. Surgery refusal or medical contraindication 
for resection or comorbidities; 3. The Eastern Cooperative 
Oncology Group (ECOG) performance status below 2; 
4. Appropriate coagulation parameters (i.e. platelet 
count above 50 000/nl, Quick > 50%, partial thrombo-
plastin time > 5 seconds) and liver parameters (bilirubin 
< 30 µmol/l); 5. Sufficient lung capacity in case of abla-
tion of pulmonary metastases (FEV1 > 1.5 l). There were 
no limitations placed upon size or location of the lesions. 
Contraindications were as follows: 1. Peritoneal carci-
nomatosis; 2. Extensive uncontrollable systemic disease; 
3. Lack of consent. With respect to these criteria, we in-
cluded 11 patients in this retrospective study (all male; 
mean age: 64.7 years; range: 52-77) with 21 unresectable 
metastases, treated with computed tomography (CT)- 
and magnetic resonance imaging (MRI)-guided IBT be-
tween April 2009 and June 2017. We treated a total of 
14 visceral metastases (including 9 liver lesions, 4 lymph 
node metastases, and one lesion located in the adrenal 
gland) and 7 lung metastases. A positive opinion from 
the ethics committee for the analysis of the patients’ data 
was obtained. All patients were discussed in an interdis-
ciplinary tumor conference, where the indication for IBT 
was determined. All patients were presented with histo-
logically proven SCC and displayed tumor progression at 
the time of referral to our institution.
Table 1. Patients characteristics
Patient Sex Age
(years)
M1 Chemotherapy 
before IBT
Localization 
of target 
lesion
Num-
ber of 
lesions 
Max 
diameter 
(cm) 
Number of
caterers 
used 
per lesion 
Dose appl. 
(Gy) 
Median 
follow-up 
(months) 
1 M 59 synchron carboplatin, 
paclitaxel
liver 1 4.1 3 20.5 3.1
2 M 52 metachron cisplatin, 
fluorouracil
lung, lymph 
node
2 5.8/2.6 3/2 11.3/10 3.2
3 M 77 metachron carboplatin, 
paclitaxel, 
cisplatin, 
fluorouracil
liver 1 6.3 5 22.5 5.6
4 M 72 metachron carboplatin, 
paclitaxel, 
cisplatin, 
fluorouracil
adrenal 
gland
1 3.4 3 20.1 6.9 
(ongoing)
5 M 67 metachron cisplatin, 
fluorouracil
lung, liver 4 1.8/0.7/ 
0.7/5.8
1/1/1/5  21.9/22.8/ 
25.3/14.3
7.3
6 M 52 synchron cisplatin, 
fluorouracil
lung 1 2.7 2 20.9 6.3
7 M 71 metachron NOS lymph node 1 1.4 5 15.4 14.7
8 M 63 metachron cisplatin, 
fluorouracil
liver 1 6.8 7 20.0 3.3
9 M 77 metachron cisplatin, 
fluorouracil
lymph node 2 2.2/2.0 1/1 20.1/19.3 10.1
10 M 63 metachron etoposid, 
cisplatin, 
fluorouracil
liver 5 3.4/2.7/ 
1.2/0.9/1.9
2/1/1/1/2 21.2/17.1/ 
22.5/22.7/ 
17.8
4.7
11 M 59 synchron NOS lung 2 1.1/0.9 1/1 22.2/15.7 21.7
All patients underwent either surgery or irradiation of the primary tumor prior to local ablation. 
Patient No 1 and No 9 received palliative chemotherapy in the time between interstitial high-dose-rate brachytherapy (HDR IBT = IBT) and progression. Furthermore, 
patient No 9 was treated with RFA of the lung 3 months after IBT 
IBT – interstitial brachytherapy; NOS – not otherwise specified 
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Prior to local ablation, ten patients received radiation 
of the primary tumor and 4 patients underwent surgical 
resection of the primary tumor. Furthermore, all patients 
had undergone palliative or adjuvant chemotherapy be-
fore IBT (detailed patient characteristics are presented in 
Table 1). Due to the size and location, two liver lesions 
were treated with MRI-guided IBT (maximum diameter 
1.2 cm and 1 cm, respectively) and other lesions were 
visualized with CT. Prior to local ablation, all patients 
received a full clinical status evaluation with a physical 
examination, laboratory assessment, whole body contrast 
enhanced CT, and a Gb-EOB-DTPA enhanced MRI of the 
liver (Primovist®, Bayer, Pharma, Leverkusen, Germany). 
All patients undergoing IBT of lung lesions had a clinical-
ly full-compensated lung function.
Study design and statistical analysis
Primary endpoint was local tumor control; second-
ary endpoints were safety, overall survival, and progres-
sion-free survival. The results were analyzed in a non- 
randomized and retrospective approach. Local tumor 
control (LTC), overall survival (OS), and progression-free 
survival (PFS) were evaluated using the Kaplan-Meier 
method with SPSS (IBM Corp. released 2013; IBM SPSS 
Statistics for Windows, version 22.0. Armonk, NY, IBM 
Corp). Safety was evaluated descriptively.
Interventional technique and irradiation
The applied methodology has been described in detail 
elsewhere [17,18]. In short, under guidance of a fluoros-
copy-CT (Toshiba, Aquilion, Japan) or real-time MRI at 
1.0 T (Panorama 1.0 T, open MR system, Philips Health-
care), 18-gauge needle were placed into target lesions. 
Subsequently, a flexible 6F catheter sheath (Radifocus, 
Terumo™, Tokyo, Japan) was inserted over a stiff angi-
ography guide wire (Amplatz, Boston Scientific, Marl-
borough, USA) using Seldinger’s-technique, followed by 
the placement of a 6F afterloading catheter (Afterload-
ingkatheter, Primed® Medizintechnik GmbH, Halber-
stadt, Germany), which ends were secured to the skin 
with a suture and covered with sterile bandages. The de-
scribed procedure was performed under a local anesthe-
sia (lidocaine), sedation (midazolam), and analgesia (fen-
tanyl). After catheter positioning, a contrast-enhanced CT 
in breath-holding technique or a gadolinium-based MRI 
scan were obtained to confirm correct catheter position-
ing and for the purpose of treatment planning. On the ac-
quired images, the target volume was outlined precisely 
as gross tumor volume (GTV), the clinical target volume 
(CTV), and adjacent organs at risk (OAR) were marked 
by the interventional radiologist and the radiooncologist. 
Treatment planning was performed using Oncentra (On-
centra® Brachy treatment planning system, Elekta AB, 
Stockholm, Sweden). Automatically calculated isodose 
lines – relative to the CTV – were controlled and adapted 
slice by slice. All irradiations were applied as a single frac-
tion irradiation using an iridium-192 source, with a nom-
inal activity of 10 Ci. A reference dose of 15-20 Gy was 
intended in our patients, which was defined as the min-
imum dose enclosing the CTV completely (D100). Higher 
doses inside the tumor volume were permitted and not 
limited. Dose limitations were taken into account inde-
pendent of adjacent organs at risk, for example gastric or 
duodenal wall (< 15 Gy/ml). After irradiation, the cath-
eters were removed, and the puncture tracts were sealed 
using gelfoam or fibrin tissue glue. Figure 1 illustrates the 
interventional technique and irradiation planning.
Follow-up
Clinical, laboratory, and imaging follow-up (contrast 
enhanced whole body CT and Gb-EOB-DTPA enhanced 
MRI of the liver – in case of treated hepatic metastases) 
was performed every three months after treatment. Lo-
Fig. 1. A) Gd-EOB-DTPA enhanced T1w MRI of a patient with liver metastasis from esophageal squamous cell carcinoma and 
sequential treatment with interstitial high-dose-rate brachytherapy (HDR IBT = IBT). White arrow indicates lesion planned for 
IBT and black arrow shows characteristic Gd-EOB-DTPA enhancement defect after irradiation of a metastases 2 weeks before; 
B) Planning MRI with marked target lesion (red line), isodose lines, and catheters; C) 3 months follow-up: white arrow indicate 
lesion treated with Gd-EOB-DTPA enhancement defect and black arrow indicate first treated lesion with constant Gd-EOB-
DTPA enhancement defect after IBT
A B C
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cal tumor control and PFS were assessed by employing 
RECIST criteria (RECIST version 1.1). Overall survival 
was calculated from the day of ablation to death. Adverse 
events were defined according to the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 4.03.
Results
The median diameter of 21 metastases was 2.2 cm 
(range: 0.7-6.8 cm). A mean of 2.3 catheters per lesion 
(range: 1-7) was employed to achieve full coverage of the 
target lesion. Ten patients were treated in one session. 
One patient received 2 sessions: patient No 5 developed 
a solitary liver metastasis 4 months after first IBT of pul-
monary and nodal lesions, and thereupon received a local 
treatment of the liver. The intended minimum tumor dose 
(D100) was 15-20 Gy, depending on localization: retroper-
itoneal lymph node and adrenal gland were intended to 
treat with 15 Gy, whereas 20 Gy was prescribed for liver 
and lung malignancies. The median D100 administered 
was 20.1 Gy (range: 10-25 Gy). In some cases, the D100 had 
to be lowered to protect adjacent risk structures. Full dose 
coverage of the GTV was achieved in 5 lung lesions and 
6 liver lesions (20 Gy, respectively), and a minimum of 
15 Gy was reached in 4 lymph node metastases (including 
retroperitoneal space) as well as in the lesion of the adre-
nal gland. During the treatment, no adjacent OAR were 
irradiated in excess of critical value. The mean irradiation 
time was 28 min (range: 11-68 min). The mean hospital 
stay of the patients was 4.4 days (range: 2-7 days). None 
of the patients experienced grade III+ adverse events re-
quiring interventions, surgery, or hospitalization. How-
ever, 4 patients received peri-interventional intravenous 
antibiosis (ciproflaxacin and metronidazole) to reduce 
the risk of a possible infection, e.g. due to treatment of 
a central liver lesion. The median follow-up time was 
6.3 months (range: 3-21.8 months). Three patients dis-
played local recurrence of the target lesion in the timespan 
of 3-7 months after IBT, resulting in a local tumor control 
of 85.7% in the Kaplan-Meier analysis (Figure 2A). The re-
current lesions were 2 lung lesions and 1 liver metastasis; 
these lesions were covered with a minimum tumor dose 
of ≥ 20 Gy at time of treatment. The progression-free in-
terval for all patients ranged from 1.3 to 13 months, with 
a median of 3.4 months (Figure 2B). During the follow-up 
period, all patients displayed a progressive systemic dis-
ease: 3 patients showed intrahepatic progression (27.3%), 
3 patients presented pulmonary progression (27.3%), and 
5 patients demonstrated progression in various locations 
(45.4%; i.e. lymph node, retroperitoneal space, bone). At 
the date of censoring, one patient of the analyzed popu-
lation was still alive (Patient No. 4 received treatment in 
June 2017). The median OS of the 10 remaining patients 
after IBT was 13.7 months (range: 5.6-25.7 months, Fig-
ure 2C). Median survival after recurrence was 6 months 
(range: 1-22 months, Figure 2D).
Discussion
Within 3 years after curative surgery, up to 88.9% of 
patients with EC develop metastases, with a median dis-
ease-free interval of 1 year after resection [4,5,6,7]. The 
post-recurrence survival is extremely poor, with a re-
ported median survival of approximately 3-7 months 
[8,19,20]. Therapy options are limited and according to 
the ESMO guidelines, a recommendation can be neither 
made for a first- nor for a second-line palliative chemo-
therapy in stage IV patients with SCC [11]. More recently, 
a phase-3, double-blind, placebo-controlled randomized 
trial with 450 patients failed to show a benefit of gefitinib 
on overall survival [20]. 
Whereas surgical resection is the method of choice 
in oligometastatic colorectal liver metastases, evidence 
for surgical resection of EC metastases is scarce [21,22]. 
Nevertheless, in metastatic EC, long-term survivors have 
been reported after resection of liver metastases in a cu-
rative intent [23]. Moreover, in 2017, van Daele et al. ret-
rospectively analyzed the outcome of 12 stage IV patients 
with EC, after a multimodal and aggressive treatment 
including surgery [24]. Furthermore, after a median fol-
low-up of 22 months (range: 8-50), 50% of the surgical pa-
tients were still alive. These findings suggest that highly 
selected candidates benefit from an aggressive curative 
approach, even in stage IV patients.
However, surgical resection is available in a limit-
ed number of cases (for instance in colorectal cancer), 
a curative resection of liver metastases is not possible in 
approximately 80% of the cases [21] but if possible, it is 
also linked to surgery-associated morbidity and mortal-
ity, regarding the extent of resection and the remaining 
functioning liver tissue. It results in prolonged stay in the 
hospital, for instance in the study mentioned above, the 
median post-operative hospital stay was 15 days (range: 
11-52 days).
In contrast, image-guided IBT provides a safe and 
minimal invasive approach. In the literature for patients 
undergoing local ablation of liver lesions or metastases of 
the retroperitoneal space, grade III-IV adverse events (i.e. 
bleeding, requiring angiographic embolization) occurred 
in up to 3%, grade I and II toxicities (e.g. nausea, eme-
sis, unspecified abdominal pain) were reported in up to 
29% [18,25]. In the study herein, we did not report any 
severe adverse event (grade III+) requiring invasive in-
tervention. The mean hospital stay was 4.4 days. In gen-
eral, patients tolerated the treatment well and could be 
discharged earlier, but due to the risk of occult bleeding, 
an observation of at least 48 hours after ablation was con-
sidered necessary.
To our knowledge, there is a limited number of stud-
ies investigating the efficacy and outcome of patients 
with metastatic EC treated with local ablation. Matsui 
et al. retrospectively evaluated LTC of 21 patients, with 
a total of 31 pulmonary metastases (mean size, 1.7 cm) 
treated with percutaneous radiofrequency ablation (RFA) 
[26]. The authors reported LTC rate of 74.2% after a me-
dian interval of 4.8 months post-RFA. Baba et al. showed 
a better LTC of 83% at 12 months after RFA of pulmonary 
SCC metastases [27].
In contrast, IBT has primarily been evaluated in met-
astatic colorectal cancer and in hepatocellular carcinoma 
(HCC), demonstrating LTC rates of 88.3% after 12 months 
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for colorectal lesions and up to 95% for HCC [15,17,28]. 
Moreover, in metastatic malignant melanoma, the LTC 
rate was reported to be 90% after a median follow-up pe-
riod of 5 months [14]. Furthermore, for metastases of gas-
tric or esophageal adenocarcinoma, Geisel et al. showed 
LTC rate of 100% over a median follow-up of 6.1 months 
post IBT [16]. In our study, we report a local tumor con-
trol of 85.7% after a median follow-up of 6.3 months. The 
reported difference might be due to very small patients’ 
population and relatively short follow-up period. There-
fore, it can be assumed that our findings go in line with 
the existing literature. Moreover, our findings correspond 
to the results of RFA studies mentioned above, even pro-
viding a better LTC compared to the investigation of Mat-
sui et al. However, RFA has well known technical limita-
tions leading to a possible incomplete ablation, including 
a large tumor mass (maximal tumor diameter of 5 cm) 
and major vessels close to the target volume inducing 
a potential cooling effect. Additionally, adverse events 
can occur due to the vicinity to critical heat sensitive or-
gans (e.g. bile duct, ureter, liver hilum). IBT in contrast is 
independent of these restrictions. 
 Survival function          Censored
Fig. 2. Kaplan-Meier curves show A) local tumor control and B) progression-free survival of patients with squamous cell car-
cinoma metastases ablated with interstitial high-dose-rate brachytherapy. Overall survival and overall survival after tumor 
progression of the same patients is depicted in C), and D) Censoring is indicated by crosses
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To our knowledge, there are only a few studies in-
vestigating the use of stereotactic body radiation therapy 
(SBRT) in the treatment of visceral or pulmonary metas-
tases of EC: two case reports combining SBRT and pallia-
tive chemotherapy [29,30], and two studies investigating 
the effect of SBRT in oligometastatic disease and in sol-
itary/limited number of nodal metastases, both studies 
including lesions of any primary site, i.e. 2 and 1 patients 
with EC, respectively [31,32].
A widespread systemic progression is known to be 
the major limiting factor for survival, concluding that our 
finding of a median PFS of 3.4 months emphasizes the 
poor overall survival of patients with metastasized EC. 
Consistently, Geisel et al. reported a median PFS of 3.5 
months in patients with metastatic esophageal adenocar-
cinoma after IBT [16].
In our study, we report a median overall survival of 
13.7 months after IBT, with a range of 5.6-25.7 months. 
These findings underline that the impact of local ablation 
on overall survival is not yet clarified, especially consid-
ering the fact that in metastasized SCC, chemotherapeu-
tic options are missing. After recurrence, the survival 
was poor with a median of 6 months corresponding to 
the findings in the literature [8]. Nevertheless, we also 
report one long-term survivor with 25 months. After an 
aggressive multimodal approach including surgery, van 
Daele et al. reported a median OS of 22 months indicating 
possible long-term survival of selected stage IV patients 
[24]. To identify appropriate candidates that might bene-
fit from local ablation with the intent to extend survival, 
a prospective trial is needed.
Therefore, the limitations of the study include its ret-
rospective nature and the low number of patients as well 
as relatively short follow-up. However, to our knowledge, 
there is little data regarding local ablation of metastatic 
EC and despite its limitations, the results of this study 
demonstrate that IBT can be safely and effectively used in 
the local control of metastasized SCC. Moreover, together 
with the findings of van Daele et al., this investigation pro-
vides an indication that a more aggressive approach could 
improve the overall survival of highly selected stage IV 
patients, with an emphasis on the advantage that IBT is 
a well-tolerated procedure with few side effects. 
Conclusions
We conclude that high-dose-rate brachytherapy is 
a safe and well-tolerated treatment in the local tumor 
control of patients with metastasized squamous cell car-
cinoma.
Disclosure
Authors report no conflict of interest.
References
1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence 
and mortality worldwide: sources, methods and major pat-
terns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-386.
2. Jain S, Dhingra S. Pathology of esophageal cancer and Bar-
rett’s esophagus. Ann Cardiothorac Surg 2017; 6: 99-109.
3. Van Rossum PSN, Mohammad NH, Vleggaar FP et al. Treat-
ment for unresectable or metastatic oesophageal cancer: cur-
rent evidence and trends. Nat Rev Gastroenterol Hepatol 2018; 
15: 235-249.
4. Nakagawa S, Kanda T, Kosugi S et al. Recurrence pattern 
of squamous cell carcinoma of the thoracic esophagus after 
extended radical esophagectomy with three-field lymph-
adenectomy. J Am Coll Surg 2004; 198: 205-211.
5. Mariette C, Balon JM, Piessen G et al. Pattern of recurrence 
following complete resection of esophageal carcinoma and 
factors predictive of recurrent disease. Cancer 2003; 97: 1616-
1623.
6. Hulscher JB, van Sandick JW, Tijssen JG et al. The recurrence 
pattern of esophageal carcinoma after transhiatal resection. 
J Am Coll Surg 2000; 191: 143-148.
7. Kunisaki C, Makino H, Takagawa R et al. Surgical outcomes 
in esophageal cancer patients with tumor recurrence after 
curative esophagectomy. J Gastrointest Surg 2008; 12: 802-810.
8. Abate E, DeMeester SR, Zehetner J et al. Recurrence after 
esophagectomy for adenocarcinoma: defining optimal fol-
low-up intervals and testing. J Am Coll Surg 2010; 210: 428-435.
9. Dresner SM, Griffin SM. Pattern of recurrence following rad-
ical oesophagectomy with two-field lymphadenectomy. Br 
J Surg 2000; 87: 1426-1433.
10. Blom RL, Lagarde SM, van Oudenaarde K et al. Survival af-
ter recurrent esophageal carcinoma has not improved over 
the past 18 years. Ann Surg Oncol 2013; 20: 2693-2698.
11. Lordick F, Mariette C, Haustermans K et al. Oesophageal 
cancer: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 2016; 27: v50-v57.
12. Weichselbaum RR, Hellman S. Oligometastases revisited. 
Nat Rev Clin Oncol 2011; 8: 378-382.
13. Aigner F, Pratschke J, Schmelzle M. Oligometastatic disease 
in colorectal cancer – how to proceed. Visc Med 2017; 33: 23-
28.
14. Bretschneider T, Mohnike K, Hass P et al. Efficacy and safe-
ty of image-guided interstitial single fraction high-dose-rate 
brachytherapy in the management of metastatic malignant 
melanoma. J Contemp Brachytherapy 2015; 7: 154-160.
15. Collettini F, Lutter A, Schnapauff D et al. Unresectable 
colorectal liver metastases: percutaneous ablation using 
CT-guided high-dose-rate brachytherapy (CT-HDBRT). Rofo 
2014; 186: 606-612. 
16. Geisel D, Denecke T, Collettini F et al. Treatment of hepatic me-
tastases from gastric or gastroesophageal adenocarcinoma with 
computed tomography-guided high-dose-rate brachytherapy 
(CT-HDRBT). Anticancer Res 2012; 32: 5453-5458.
17. Ricke J, Wust P, Stohlmann A et al. CT-guided interstitial 
brachytherapy of liver malignancies alone or in combination 
with thermal ablation: phase I-II results of a novel technique. 
Int J Radiat Oncol Biol Phys 2004; 58: 1496-1505.
18. Bretschneider T, Ricke J, Gebauer B, Streitparth F. Im-
age-guided high-dose-rate brachytherapy of malignancies in 
various inner organs - technique, indications, and perspec-
tives. J Contemp Brachytherapy 2016; 8: 251-261.
19. Parry K, Visser E, van Rossum PS et al. Prognosis and treat-
ment after diagnosis of recurrent esophageal carcinoma fol-
lowing esophagectomy with curative intent. Ann Surg Oncol 
2015; 22 (Suppl 3): S1292-1300.
20. Dutton SJ, Ferry DR, Blazeby JM et al. Gefitinib for oesopha-
geal cancer progressing after chemotherapy (COG): a phase 3, 
multicentre, double-blind, placebo-controlled randomised 
trial. Lancet Oncol 2014; 15: 894-904.
21. Garden OJ, Rees M, Poston GJ et al. Guidelines for resection 
of colorectal cancer liver metastases. Gut 2006; 55: iii1-iii8.
22. Nguyen KT, Laurent A, Dagher I et al. Minimally invasive 
liver resection for metastatic colorectal cancer: a multi-insti-
Journal of Contemporary Brachytherapy (2018/volume 10/number 5)
IBT of esophageal SCC metastases 445
tutional, international report of safety, feasibility, and early 
outcomes. Ann Surg 2009; 250: 842-848.
23. Huddy JR, Thomas RL, Worthington TR, Karanjia ND. Liver 
metastases from esophageal carcinoma: is there a role for sur-
gical resection? Dis Esophagus 2015; 28: 483-487.
24. Van Daele E, Scuderi V, Pape E et al. Long-term survival af-
ter multimodality therapy including surgery for metastatic 
esophageal cancer. Acta Chir Belg 2018; 118: 227-232.
25. Mohnike K, Neumann K, Hass P et al. Radioablation of 
adrenal gland malignomas with interstitial high-dose-rate 
brachytherapy: Efficacy and outcome. Strahlenther Onkol 
2017; 193: 612-619. 
26. Matsui Y, Hiraki T, Gobara H et al. Percutaneous radiofre-
quency ablation for pulmonary metastases from esophageal 
cancer: retrospective evaluation of 21 patients. J Vasc Interv 
Radiol 2014; 25: 1566-1572.
27. Baba Y, Watanabe M, Kawanaka K et al. Radiofrequency ab-
lation for pulmonary metastases from esophageal squamous 
cell carcinoma. Dis Esophagus 2014; 27: 36-41.
28. Mohnike K, Wieners G, Schwartz F et al. Computed tomog-
raphy-guided high-dose-rate brachytherapy in hepatocel-
lular carcinoma: safety, efficacy, and effect on survival. Int 
J Radiat Oncol Biol Phys 2010; 78: 172-179.
29. Katano A, Yamashita H, Nakagawa K. Stereotactic body ra-
diotherapy for oligo-recurrence in the liver in a patient with 
esophageal carcinoma: A case report. Mol Clin Oncol 2017; 7: 
1061-1063.
30. Egawa T, Okubo Y, Kemmochi T et al. A case of liver metas-
tasis from esophageal cancer treated with stereotactic body 
radiation therapy. Gan To Kagaku Ryoho 2013; 40: 1850-1852.
31. Milano MT, Katz AW, Zhang H et al. Oligometastases treat-
ed with stereotactic body radiotherapy: long-term follow-up 
of prospective study. Int J Radiat Oncol Biol Phys 2012; 83: 
878-886.
32. Yeung R, Hamm J, Liu M, Schellenberg D. Institutional anal-
ysis of stereotactic body radiotherapy (SBRT) for oligometa-
static lymph node metastases. Radiat Oncol 2017; 12: 105.
